These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 32915435

  • 1. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C, Tonacchera M.
    Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
    [Abstract] [Full Text] [Related]

  • 2. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
    Araujo-Castro M, Parra Ramírez P, Martín Rojas-Marcos P, García Centeno R, Gracia Gimeno P, Tomé Fernández-Ladreda M, Sampedro Núñez MA, Higueruela C, Robles Lázaro C.
    Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
    [Abstract] [Full Text] [Related]

  • 3. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, Cuesta Hernández M, Sampedro Núñez MA, Marazuela M.
    Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
    [Abstract] [Full Text] [Related]

  • 4. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
    Tsagarakis S, Kokkoris P, Roboti C, Malagari C, Kaskarelis J, Vlassopoulou V, Alevizaki C, Thalassinos N.
    Clin Endocrinol (Oxf); 1998 May; 48(5):627-33. PubMed ID: 9666875
    [Abstract] [Full Text] [Related]

  • 5. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.
    Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L, Nuzzo V, Lombardi G.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1440-8. PubMed ID: 10770179
    [Abstract] [Full Text] [Related]

  • 6. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
    Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C, Thalassinos N.
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
    [Abstract] [Full Text] [Related]

  • 7. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
    [Abstract] [Full Text] [Related]

  • 8. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M, García Cano AM, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
    [Abstract] [Full Text] [Related]

  • 9. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
    Araujo-Castro M, Hanzu FA, Pascual-Corrales E, García Cano AM, Marchan M, Escobar-Morreale HF, Valderrabano P, Casals G.
    Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases.
    Brox-Torrecilla N, García Cano AM, Valderrábano P, Quintero Tobar A, Escobar-Morreale HF, Araujo-Castro M.
    Endocrine; 2023 Sep; 81(3):484-491. PubMed ID: 37212980
    [Abstract] [Full Text] [Related]

  • 11. Adrenal incidentaloma as a novel independent predictive factor for periodontitis.
    Rodrigues MO, Moraes AB, de Paula MP, Pereira VA, Leão ATT, Vieira Neto L.
    J Endocrinol Invest; 2021 Nov; 44(11):2455-2463. PubMed ID: 33788166
    [Abstract] [Full Text] [Related]

  • 12. Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study.
    Araujo-Castro M, Casals G, Hanzu FA, Pascual-Corrales E, García Cano AM, Lanza VF, Luis Del Rey Mejías Á, Marchan M, Escobar-Morreale HF, Valderrabano P.
    Clin Endocrinol (Oxf); 2023 Feb; 98(2):165-176. PubMed ID: 35973974
    [Abstract] [Full Text] [Related]

  • 13. The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients' stratification by body mass index and age.
    Podbregar A, Janez A, Goricar K, Jensterle M.
    BMC Endocr Disord; 2020 Jul 31; 20(1):118. PubMed ID: 32736549
    [Abstract] [Full Text] [Related]

  • 14. Subclinical Cushing's syndrome in adrenal incidentaloma.
    Terzolo M, Osella G, Alì A, Borretta G, Cesario F, Paccotti P, Angeli A.
    Clin Endocrinol (Oxf); 1998 Jan 31; 48(1):89-97. PubMed ID: 9509073
    [Abstract] [Full Text] [Related]

  • 15. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
    Araujo-Castro M, Mínguez Ojeda C, Sánchez Ramírez MN, Gómez Dos Santos V, Pascual-Corrrales E, Fernández-Argüeso M.
    Endocrine; 2022 Oct 31; 78(1):142-150. PubMed ID: 35751779
    [Abstract] [Full Text] [Related]

  • 16. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.
    Androulakis II, Kaltsas GA, Kollias GE, Markou AC, Gouli AK, Thomas DA, Alexandraki KI, Papamichael CM, Hadjidakis DJ, Piaditis GP.
    J Clin Endocrinol Metab; 2014 Aug 31; 99(8):2754-62. PubMed ID: 24712565
    [Abstract] [Full Text] [Related]

  • 17. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM.
    Eur J Endocrinol; 2023 Jul 20; 189(1):G1-G42. PubMed ID: 37318239
    [Abstract] [Full Text] [Related]

  • 18. Adrenal incidentaloma: an overview of hormonal data from the National Italian Study Group.
    Mantero F, Masini AM, Opocher G, Giovagnetti M, Arnaldi G.
    Horm Res; 1997 Jul 20; 47(4-6):284-9. PubMed ID: 9167966
    [Abstract] [Full Text] [Related]

  • 19. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
    Patrova J, Kjellman M, Wahrenberg H, Falhammar H.
    Endocrine; 2017 Nov 20; 58(2):267-275. PubMed ID: 28887710
    [Abstract] [Full Text] [Related]

  • 20. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
    Yener S, Baris M, Peker A, Demir O, Ozgen B, Secil M.
    Clin Endocrinol (Oxf); 2017 Nov 20; 87(5):425-432. PubMed ID: 28656620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.